159 related articles for article (PubMed ID: 26803204)
1. Identification of initial leads directed at the calmodulin-binding region on the Src-SH2 domain that exhibit anti-proliferation activity against pancreatic cancer.
Tzou YM; Bailey SK; Yuan K; Shin R; Zhang W; Chen Y; Singh RK; Shevde LA; Krishna NR
Bioorg Med Chem Lett; 2016 Feb; 26(4):1237-44. PubMed ID: 26803204
[TBL] [Abstract][Full Text] [Related]
2. Calmodulin mediates Fas-induced FADD-independent survival signaling in pancreatic cancer cells via activation of Src-extracellular signal-regulated kinase (ERK).
Yuan K; Jing G; Chen J; Liu H; Zhang K; Li Y; Wu H; McDonald JM; Chen Y
J Biol Chem; 2011 Jul; 286(28):24776-84. PubMed ID: 21613217
[TBL] [Abstract][Full Text] [Related]
3. A preclinical evaluation of SKLB261, a multikinase inhibitor of EGFR/Src/VEGFR2, as a therapeutic agent against pancreatic cancer.
Pan Y; Zheng M; Zhong L; Yang J; Zhou S; Qin Y; Xiang R; Chen Y; Yang SY
Mol Cancer Ther; 2015 Feb; 14(2):407-18. PubMed ID: 25519702
[TBL] [Abstract][Full Text] [Related]
4. Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.
Yuan K; Yong S; Xu F; Zhou T; McDonald JM; Chen Y
Oncotarget; 2015 Sep; 6(28):25308-19. PubMed ID: 26320171
[TBL] [Abstract][Full Text] [Related]
5. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms underlying the cytotoxicity of a novel quinazolinedione-based redox modulator, QD232, in pancreatic cancer cells.
Pathania D; Kuang Y; Sechi M; Neamati N
Br J Pharmacol; 2015 Jan; 172(1):50-63. PubMed ID: 25047070
[TBL] [Abstract][Full Text] [Related]
7. Recent progress of Src SH2 and SH3 inhibitors as anticancer agents.
Lu XL; Cao X; Liu XY; Jiao BH
Curr Med Chem; 2010; 17(12):1117-24. PubMed ID: 20158477
[TBL] [Abstract][Full Text] [Related]
8. Bone-targeted Src SH2 inhibitors block Src cellular activity and osteoclast-mediated resorption.
Violette SM; Guan W; Bartlett C; Smith JA; Bardelay C; Antoine E; Rickles RJ; Mandine E; van Schravendijk MR; Adams SE; Lynch BA; Shakespeare WC; Yang M; Jacobsen VA; Takeuchi CS; Macek KJ; Bohacek RS; Dalgarno DC; Weigele M; Lesuisse D; Sawyer TK; Baron R
Bone; 2001 Jan; 28(1):54-64. PubMed ID: 11165943
[TBL] [Abstract][Full Text] [Related]
9. Synergistic Anti-Cancer Effects of AKT and SRC Inhibition in Human Pancreatic Cancer Cells.
Ahn K; O YM; Ji YG; Cho HJ; Lee DH
Yonsei Med J; 2018 Aug; 59(6):727-735. PubMed ID: 29978609
[TBL] [Abstract][Full Text] [Related]
10. Mutational investigation of the specificity determining region of the Src SH2 domain.
Bradshaw JM; Mitaxov V; Waksman G
J Mol Biol; 2000 Jun; 299(2):521-35. PubMed ID: 10860756
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacodynamic evaluation of a new Src/FOSL1 inhibitor, LY-1816, in pancreatic ductal adenocarcinoma.
Yang W; Meng L; Chen K; Tian C; Peng B; Zhong L; Zhang C; Yang X; Zou J; Yang S; Li L
Cancer Sci; 2019 Apr; 110(4):1408-1419. PubMed ID: 30618127
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of Src SH2 by a novel thiol-targeting tricarbonyl-modified inhibitor and mechanistic analysis by (1)H/(13)C NMR spectroscopy.
Sundaramoorthi R; Siedem C; Vu CB; Dalgarno DC; Laird EC; Botfield MC; Combs AB; Adams SE; Yuan RW; Weigele M; Narula SS
Bioorg Med Chem Lett; 2001 Jul; 11(13):1665-9. PubMed ID: 11425533
[TBL] [Abstract][Full Text] [Related]
13. Selective Targeting of SH2 Domain-Phosphotyrosine Interactions of Src Family Tyrosine Kinases with Monobodies.
Kükenshöner T; Schmit NE; Bouda E; Sha F; Pojer F; Koide A; Seeliger M; Koide S; Hantschel O
J Mol Biol; 2017 May; 429(9):1364-1380. PubMed ID: 28347651
[TBL] [Abstract][Full Text] [Related]
14. Novel mechanism of regulation of the non-receptor protein tyrosine kinase Csk: insights from NMR mapping studies and site-directed mutagenesis.
Shekhtman A; Ghose R; Wang D; Cole PA; Cowburn D
J Mol Biol; 2001 Nov; 314(1):129-38. PubMed ID: 11724538
[TBL] [Abstract][Full Text] [Related]
15. Targeting the yin and the yang: combined inhibition of the tyrosine kinase c-Src and the tyrosine phosphatase SHP-2 disrupts pancreatic cancer signaling and biology in vitro and tumor formation in vivo.
Gomes EG; Connelly SF; Summy JM
Pancreas; 2013 Jul; 42(5):795-806. PubMed ID: 23271399
[TBL] [Abstract][Full Text] [Related]
16. A Src SH2 selective binding compound inhibits osteoclast-mediated resorption.
Violette SM; Shakespeare WC; Bartlett C; Guan W; Smith JA; Rickles RJ; Bohacek RS; Holt DA; Baron R; Sawyer TK
Chem Biol; 2000 Mar; 7(3):225-35. PubMed ID: 10712930
[TBL] [Abstract][Full Text] [Related]
17. Recent advances in the design and synthesis of SH2 inhibitors of Src, Grb2 and ZAP-70.
Vu CB
Curr Med Chem; 2000 Oct; 7(10):1081-100. PubMed ID: 10911019
[TBL] [Abstract][Full Text] [Related]
18. A Discovery Strategy for Selective Inhibitors of c-Src in Complex with the Focal Adhesion Kinase SH3/SH2-binding Region.
Moroco JA; Baumgartner MP; Rust HL; Choi HG; Hur W; Gray NS; Camacho CJ; Smithgall TE
Chem Biol Drug Des; 2015 Aug; 86(2):144-55. PubMed ID: 25376742
[TBL] [Abstract][Full Text] [Related]
19. Binding, domain orientation, and dynamics of the Lck SH3-SH2 domain pair and comparison with other Src-family kinases.
Hofmann G; Schweimer K; Kiessling A; Hofinger E; Bauer F; Hoffmann S; Rösch P; Campbell ID; Werner JM; Sticht H
Biochemistry; 2005 Oct; 44(39):13043-50. PubMed ID: 16185072
[TBL] [Abstract][Full Text] [Related]
20. Loss of tyrosine phosphatase-dependent inhibition promotes activation of tyrosine kinase c-Src in detached pancreatic cells.
Connelly SF; Isley BA; Baker CH; Gallick GE; Summy JM
Mol Carcinog; 2010 Dec; 49(12):1007-21. PubMed ID: 20945416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
